Aripiprazole for the management of schizophrenia in the japanese population: A systematic review and meta-analysis of randomized controlled trials

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 419-434

  Kishi, Taro ^a   Matsuda, Yuki ^a   Matsunaga, Shinji ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; Effcacy; Japan; Meta analysis; Safety; Systematic review

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; CLOSPIPRAMINE; HALOPERIDOL; OLANZAPINE; PEROSPIRONE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

AKATHISIA; ARTICLE; BODY WEIGHT; BRADYKINESIA; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GAIT DISORDER; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; JAPANESE (PEOPLE); META ANALYSIS; MUSCLE RIGIDITY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; POWERLESSNESS; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 84923307665     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S78977     Document Type: Article

References (38)

1. Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013;47(2):149–154.
2. Kishi T, Iwata N. Effcacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013;27(9):731–741.
3. Leucht S, Cipriani A, Spineli L, et al. Comparative effcacy and toler-ability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
4. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–233.
5. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.
6. Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014;348:g1173.
7. Mattila T, Wohlfarth T, Koeter M, et al. Geographic variation in effcacy of atypical antipsychotics for the acute treatment of schizophrenia – an individual patient data meta-analysis. Eur Neuropsychopharmacol. 2014;24(7):1067–1077.
8. Zandi PP, Judy JT. The promise and reality of pharmacogenetics in psychiatry. Clin Lab Med. 2010;30(4):931–974.
9. Reynolds GP. The pharmacogenetics of symptom response to antipsy-chotic drugs. Psychiatry Investig. 2012;9(1):1–7.
10. Mulligan MJ, Vasu R, Grossi CE, et al. Neoplastic meningitis with eosino-philic pleocytosis in Hodgkin’s disease: a case with cerebellar dysfunction and a review of the literature. Am J Med Sci. 1988;296(5):322–326.
11. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dop-amine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A. 2007; 104(51):20552–20557.
12. Munro J, O’Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576–580.
13. Danaei G, Finucane MM, Lu Y, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.
14. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688.
15. Stauffer VL, Sniadecki JL, Piezer KW, et al. Impact of race on eff-cacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder. BMC Psychiatry. 2010;10:89.
16. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet. 2003;361(9351):85.
17. Slomko H, Heo HJ, Einstein FH. Minireview: Epigenetics of obesity and diabetes in humans. Endocrinology. 2012;153(3):1025–1030.
18. Choi JH, Yo o H W. Control of puberty: genetics, endocrinology, and environment. Curr Opin Endocrinol Diabetes Obes. 2013;20(1):62–68.
19. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012; 69(9):904–912.
20. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet. 2008;83(4):445–456.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
22. 031-95-003 (study name). Clinical evaluation of aripiprazole in schizophrenic patients: A comparative double-blind study with mosapramine. Available from: http://www.info.pmda.go.jp/shinyaku/P200600001/18007800_21800AMZ10011_G100_1.pdf#search=’03195003’. Accessed November 12, 2014. Japanese.
23. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113(1):49–55.
24. Ishigooka J, Miura S, Koyama T, et al. Clinical evaluation of arip-iprazole in schizophrenic patients: A comparative double-blind study with haloperidol. Rinsho Seishin Yakuri [Japanese Journal of Clinical Psychopharmacology]. 2006;9(2):295–329. Japanese.
25. Takekita Y, Kato M, Wakeno M, et al. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:110–114.
26. Sato G, Yoshimura S, Yamashita H, Okamoto Y, Yamawaki S. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima J Med Sci. 2012;61(4):75–83.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
28. Inada T, Yagi G. Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Keio J Med. 1996;45(2):95–99.
29. Inada T, Yagi G, Miura S. Extrapyramidal symptom profles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2–3):227–238.
30. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-hand-book.org.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
33. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus frst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
34. Khanna P, Komossa K, Rummel-Kluge C, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;2:CD006569.
35. Park JI, Cho DH, Hahn SW, Jeong B, Kim JH, Kim SW, Koo MS, Lee SH, Lee SJ, Lee YH, Park JI, Rho SH, Chung YC.The advantage of using 3-week data to predict response to aripiprazole at week 6 in frst-episode psychosis. Int Clin Psychopharmacol. 2014;29(2):77–85.
36. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during frst-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.
37. Su YP, Chang CK, Hayes RD, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014;130(1):52–60.
38. Kimura G, Kadoyama K, Brown JB, et al. Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database. Int J Med Sci. 2015; Jan 5;12(2):135–140.